Short-Term Effects of Pecavaptan on Weight and Congestion in Acute Heart Failure: The AVANTI Post-Hoc Analysis
{{output}}
Background: Pecavaptan, a dual vasopressin V1a/V2-receptor antagonist, did not enhance weight loss by day 30 in hospitalized heart failure (HF) patients. However, its short-term effects remain unclear. ... ...
